Sam Brusco, Associate Editor06.09.23
SurGenTec has gained U.S. Food and Drug Administration (FDA) clearance for its TiLink-L sacroiliac (SI) joint fusion system.
The SI joint implant can be implanted from a lateral or posterior/oblique approach and its surface technology helps optimize bone growth. According to the company, this implant will be the inaugural “first implant in the sacroiliac family of products.”
Its design allows for excellent compression across the joint and the Nanotex surface tech has demonstrated bony in-growth and on-growth. TiLink-L also features a helical self-harvesting channel to capture the patient’s own bone and encourage healing. Graft windows are strategically placed between threads to allow for potential fusion through the screw to boost stability.
Posterior oblique approach.
"We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products,” Travis Greenhalgh, CEO at SurGenTec told the press. "With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care.”
The SI joint implant can be implanted from a lateral or posterior/oblique approach and its surface technology helps optimize bone growth. According to the company, this implant will be the inaugural “first implant in the sacroiliac family of products.”
Its design allows for excellent compression across the joint and the Nanotex surface tech has demonstrated bony in-growth and on-growth. TiLink-L also features a helical self-harvesting channel to capture the patient’s own bone and encourage healing. Graft windows are strategically placed between threads to allow for potential fusion through the screw to boost stability.
Posterior oblique approach.
"We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products,” Travis Greenhalgh, CEO at SurGenTec told the press. "With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care.”
